Aesthetic Polyclinic Abu Dhabi

 

 

 

 

 

Aesthetic Polyclinic Abu Dhabi

Global Stem Cells Group has named Aesthetic Polyclinic in Abu Dhabi, UAE, exclusive representative for GSCG in that city.

MIAMI, Nov. 9, 2017—Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, has added Aesthetic Polyclinic to its worldwide regenerative medicine network, naming it the exclusive representative for GSCG in Abu Dhabi.

This new alliance is part of Global Stem Cells Group’s worldwide expansion of its clinical presence, partnering with qualified physicians experienced in stem cell therapies to open new clinics and utilize GSCG stem cell products and protocols in patient treatments. To date, GSCG has established similar alliances in 32 cities worldwide.

Aesthetic Polyclinic will provide advanced stem cell protocols and state-of-the-art techniques in stem cell therapies to patients from around the world. Aesthetic Polyclinic is GSCG’ fourth clinical presence in the Middle East, including Morocco, Iraq, and Pakistan.

Aesthetic Polyclinic specializes in plastic surgery, aesthetic medicine, dermatology, and general and cosmetic dentistry. The alliance with GSCG will add the benefits of stem cell applications for aesthetic and anti-aging treatments to the organization’s catalog of patient services. According to Sela Al Asadi, Managing Director for Aesthetic Polyclinic, the alliance is ideally suited to both organizations’ mission.

“Like Global Stem Cells Group, we are committed to meeting the growing needs of our clients and patients, and we continuously search for and adopt the latest medical technology and services,” Al Asadi says. “Our staff of committed, efficient, and customer-centric professionals is excited to represent Global Stem Cells Group and offer the benefits of their regenerative medicine products and protocols to our patients.”

Global Stem Cells Group provides stem cell treatments for a variety of conditions, diseases, and aesthetic treatments at facilities worldwide. The new facility will have an international staff that is experienced in administering the leading cellular therapies available.

Global Stem Cells Group’s Abu Dhabi clinic is certified for the medical tourism market, and staff physicians are board-certified or board-eligible. GSCG clinics provide services in more than 10 specialties, attracting patients from the United States and around the world.

Global Stem Cells Group is committed to providing the highest standards of services and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

To learn more about Global Stem Cells Group, visit the GSCG website,  email info@stemcellsgroup.com, or call +1305 560 533

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global Stem Cell Group’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

About Aesthetic Polyclinic

Aesthetic Polyclinic has been serving the residents of Abu Dhabi and Al Ain since 2000, providing world-class aesthetic services including plastic surgery dermatology, IPL hair removal, cosmetic and general dentistry, weight loss and body treatments, and specialized skin care.

One of Abu Dhabi’s top healthcare clinics, Aesthetic Polyclinic values the distinctly individual nature of all its clients and patients and prides itself in delivering quality customer service through customer focus, innovation, cutting-edge technology, and a commitment to excellence.

Formerly Aesthetic Skincare, it became Aesthetic Polyclinic in 2009 upon introducing dermatology and plastic surgery services. In 2013, the organization expanded its medical services with a brand new, state-of-the-art dedicated medical building and introducing dental and orthodontic services.

###

Aesthetic Polyclinic

 

Adimarket launches website

 

 

 

 

 

 

Adimatket launches website

 

AdiMarket has launched a new website offering regenerative medicine customers new product and purchasing options on an e-commerce mega-store scale.

MIAMI, Nov. 9, 2017—Adimarket, a leading provider of in-office regenerative medicine products and solutions, has changed its corporate mission and launched a new website to reflect its new direction toward online mega-store status. The aim is to become the eBay or Amazon of regenerative medicine products.

Adimarket, a subsidiary of Global Stem Cells Group, has a new mission that borrows from marketplace strategies used by e-commerce giants Amazon and eBay, which means more products and more buying options for regenerative medicine practitioners.

eBay and Amazon are arguably the two biggest e-commerce sites out there, but they function very differently. AdiMarket’s new website utilizes e-commerce strategies of both. eBay’s model takes no inventory and acts as an intermediary that facilitates peer-to-peer (P2P) commerce. Amazon, in addition to warehousing inventory, utilizes an end-to-end production to consumer (P2C) model that allows buyers to purchase from independent companies directly from the Amazon website, and products are shipped directly from producers to consumers, with no intermediary necessary for greater convenience.

Despite their contrary e-commerce strategies, Amazon and eBay are each other’s fiercest competitors. Both companies’ approaches have pros and cons—it’s the pros of the two strategies that AdiMarket is leveraging to achieve its new corporate mission. The company will stock and promote regenerative medicine products for specific brands and manufacturers, and at the same time promote products from all providers of regenerative medicine products, systems, kits, and equipment using P2C commerce platform as well as a peer-to-peer (P2P) platform.

“We’re positioning Adimarket to become the largest e-commerce marketplace for all things regenerative medicine,” says Benito Novas, founder and CEO of Global Stem Cells Group. “We aim to be the go-to, one-stop-shop for all regenerative medicine that physicians and practitioners want or need.”

In addition, AdiMarket now has the capabilities to build and install high-performing in-office laboratories for physicians and practitioners requiring more complex lab equipment for stem cell culturing, expansion, and cryopreservation.
To learn more about Adimarket’s new mission and expanded e-commerce marketplace, visit https://www.adimarket.netemail, email info@stemcellsgroup.com, or call +1305 560 5337.

About AdiMarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

###

Adimarket launches website

XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery

 

 

 

 

 

 

 

The International Society for Stem Cell Application (ISSCA), and Global Stem Cells Group (GSCG) will sponsor the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery Obesity. ISSCA and GSCG will launch their new online regenerative medicine training course, and will also launch a new adipose stem cell isolation kit, STEMPIA, at the event.

XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery .                   XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery


MIAMI, Nov. 9, 2017— The International Society for Stem Cell Application (ISSCA), a global leader in promoting education and setting standards in regenerative medicine, in collaboration with and Global Stem Cells Group (GSCG) will sponsor the XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery and Obesity Nov. 30 – Dec. 3, 2017, in Mexico City.

Hosted by the Institute of Higher Studies in Medicine (IESM), the annual International Congress is among the largest and most well-attended aesthetic medicine events in Ibero-America. More than 1,000 physicians from around the world are expected to attend. This year’s speaker lineup includes a renowned group of professionals in the field of regenerative medicine.

ISSCA and GSCG plan to leverage the large gathering of regenerative medicine and healthcare professionals at the International Congress to launch the newest cutting-edge online regenerative medicine training course in collaboration with Stem Cell Training, Inc.

The new virtual regenerative medicine training course is designed to instruct qualified physicians in the theoretical and practical protocols necessary to effectively and expertly administer regenerative medicine procedures to their patients. Training includes instructions for harvesting and isolating stem cells. The online training program positions physicians to provide stem cell procedures in their existing practice or open a stem cell center practice and join ISSCA’s international network of stem cell specialists.

In addition, the organizations will launch STEMPIA, a new adipose-derived stem call kit. The kit provides two specially designed tubes to isolate and concentrate adipose tissue-derived stromal vascular fraction (SVF). STEMPIA offers an easier, more effective, and shorter process for SVF isolation while maintaining high viability rates. STEMPIA uses less consumables and tools compared to manual SVF isolation processes, saving both costs and time in the SVF isolation process.

ISSCA, and GSCG will also be conducting a two-day, intensive regenerative medicine certification course for qualified physicians in Mexico City following the congress. Attendees will gain hand-on training and learn how to harvest and isolate stem cells, and expertly administer stem cell treatments to patients.. Upon completing the course, participants will receive certification and will be able to use their skills to treat patients in their practice, and for career advancement.

Fiesta Americana Reforma is the conference venue and headquarters. Visit the hotel data website page for location and additional information.

To learn more about the International Conference, visit the conference website email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

###

XVIII International Congress of Aesthetic Medicine, Aesthetic Surgery Obesity

iISSCA 2018 Korea Fellowship

 

 

 

 

 

The International Society for Stem Cell Application (ISSCA) has scheduled the first Cell Therapy and Tissue Engineering Fellowship in the upcoming year for March 5, 2018. The 6-day immersive program will be held in Seoul, Korea.

ISSCA 2018 Korea Fellowship

MIAMI, Nov. 9, 2017—The International Society for Stem Cell Application (ISSCA), a global leader in regenerative medicine education, research, and certification, will hold the first Cell Therapy and Tissue Engineering fellowship for the upcoming year on March 5, 2018, in Seoul, Korea.

Following up on the success of the organization’s series of fellowships in 2017, ISSCA decided to continue to offer the opportunity to graduate and post-doctoral students. Participants will engage with world-class stem cell and regenerative medicine experts in an immersive, hands-on experience focused on stem cell characterization and laboratory applications including cell culture, plating, trypsinization, harvesting, and cryopreservation. Fellowship attendants also gain an understanding of control tests including cell count, viability, flow cytometry, endotoxin, mycoplasma, and sterility.

“The very nature of stem cell therapy and tissue engineering necessitates practical, immersive, and skillfully monitored participation for students training in the application of stem cells,” says Benito Novas, ISSCA Public Relations Director and founder of Global Stem Cells Group. “The opportunity to actively engage while learning theoretical and analytical methods from mentors working to create new medical technologies and laboratory applications in one of the most rapidly growing areas of biomedical engineering is highly advantageous.

“Bio-medical scientists encounter many challenges before tissue engineering therapies reach clinical use and widespread application,” Novas says. “Cell therapy and tissue engineering offer vast potential for a career as a practitioner or researcher in which today’s students can be tomorrow’s pioneers in improving the efficacy of medical treatments and advancing the healthcare industry.”

And since so many tissues and organs are excellent candidates for engineering new treatments and cures for diseases, including blood vessel, bone, cartilage, liver, pancreas, peripheral nerve, and skin cells, the future of regenerative medicine has the potential to revolutionize disease remediation and tissue repair

The ISSCA Fellowship in Cell Therapy and Tissue Engineering is a 6-day workshop that offers a certificate of completion issued by ISSCA and Westminster International University in Seoul.  Students who complete the fellowship become members of the ISSCA’s international network of regenerative medical professionals and standard setters, with access to events, resources, training, and support moving forward.

ISSCA is the only organization that provides a complete Cell Therapy and Engineering Tissue Fellowship focused on regenerative medicine. It is also the only fellowship of its kind supported by Korean Universities.

To learn more about the ISSCA fellowship and to reserve a spot at the March 8, 2018 program in Korea, visit http://stemcellsacademy.com, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training, and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

###

.

ISSCA 2018 Korea Fellowship

regenerative-medicine-certification-training

 

 

 

 

 

 

 

The International Association for Stem Cell Application (ISSCA) will be conducting a regenerative medicine certification course for physicians in Buenos Aires Nov. 26-27, 2017. The two-day intensive training course teaches trainees extraction, isolation, and application of PRP, adipose, and bone marrow stem cells.

 

regenerative medicine certification training

MIAMI, Nov. 9, 2017— The International Society for Stem Cell Application (ISSCA), a global leader in regenerative medicine training, has announced plans to conduct regenerative medicine certification training for physicians in Buenos Aires, Argentina November 26 – 27, 2017.

The ISSCA training course, available to qualified physicians interested in adding regenerative medicine to their practice procedures, provides hands-on, practical instruction under the guidance of trained medical experts in a highly visual, interactive, and clinical learning environment.

.ISSCA’s medical professionals teach reintegration and procedural techniques on live patients using different protocols for isolating stem cells. Trainees will participate in different medical cases under the supervision of trained specialists.

This hands-on stem cell training course provides each participant with a live demonstration of the extraction, isolation, and application of PRP, adipose, and bone marrow stem cells. Techniques and materials used in the course, along with high-resolution, step-by-step procedure videos are provided for the participating physician’s future use and reference.

Led by ISSCA’s established team of skilled practitioners, this course is designed specifically to provide personalized instruction. Seats for each course are limited to 8-10 trainees, not only to suit each participant’s individual training needs but also to allow for professional networking.

Participants who complete the training will receive certification that documents their participation in and completion of the training, their and their knowledge and skills in the field of regenerative medicine. Certification candidates are required to provide proof of prior medical training and experience, and successfully complete a written as well as an oral/practical exam. Certification confirms a physician’s expertise in regenerative medicine.

​Certification procedures and requirements are key to the integrity of regenerative medicine. They furnish a reputable credential that is essential not only for patients to see, but also to a physician’s practice.

The Buenos Aires certification training course will mark the 11th event ISSCA has sponsored and hosted thus far in 2017. The organization is working to position itself as a reference point for regenerative medical practitioners worldwide. With a presence in more than 25 countries, physicians interested in certification can check for an ISSCA training course near them by visiting the https://www.stemcelltraining.net/ website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

.                                                                                                               ###
Regenerative medicine certification training

a4m-25th-annual-world-congress

(Pictured at left) Integrated Stem Cell Work Station, a new multi-functional bio-work station from AdiMarket,

 

 

 

 

 

Adimarket, a division of Global Stem Cells Group announces its sponsorship of the 25th Annual American Academy of Anti-Aging Medicine (A4M) World Congress in Las Vegas Dec. 14-16. GSCG plans to launch two new products for stem cell and regenerative medicine practitioners at the event.

a4m-25th-annual-world-congress

 

MIAMI, Nov. 9, 2017—Adimarket, a division of Global Stem Cells Group (GSCG), a world leader in stem cell and regenerative medicine, announces its sponsorship of the 25th Annual American Academy of Anti-Aging Medicine (A4M) World Congress in Las Vegas, Dec. 14 – 16, 2017. This year marks a quarter-century in A4M’s mission to build awareness and deliver innovative, cutting-edge scientific education in the field of anti-aging medicine.

A4M focuses on longevity and prolonging the lifespan of people worldwide. Global Stem Cells Group shares A4M’s commitment to promoting anti-aging medicine, having organized five regenerative medicine symposiums and other medical conferences highlighting anti-aging research and therapies in 2017.

 

a4m 25th annual world congress

Global Stem Cells Group will leverage the large gathering of regenerative medicine and healthcare professionals at theInternational Congress to launch its newest cutting-edge online regenerative medicine training course in collaboration with StemCell Training, Inc.

The new virtual regenerative medicine training course is designed to instruct qualified physicians in the theoretical and practical protocols necessary to effectively and expertly administer regenerative medicine procedures to their patients. Training includes instructions for harvesting and isolating stem cells. The online training program positions physicians to provide stem cell procedures in their existing practice or open a stem cell center practice and join ISSCA’s international network of stem cell specialists.

GSCG will also launch two new products at the A4M conference:

  1. STEMPIA, a new adipose-derived stem cell kit. The kit provides two specially designed tubes to isolate and concentrate adipose tissue-derived stromal vascular fraction (SVF). STEMPIA offers an easier, more effective, and shorter process for SVF isolation while maintaining high viability rates. STEMPIA uses fewer consumables and tools compared to manual SVF isolation processes, saving both costs and time in the SVF isolation process.
  2. The latest Integrated Stem Cell Work Station from AdiMarket, a multi-functional bio-work station that allows physicians to perform stem cell protocols and procedures within an enclosed controlled culture environment. The Integrated Stem Cell Work Station is equipped with a built-in centrifuge, shaking incubator, laminar flow hood and other features to ensure a clean environment for stem cell isolation and handling. It can also be customized to accommodate insertion of supplementary device(s) in work station.

The American Academy of Anti-Aging Medicine (A4M) 25th Annual World Congress will be hosted at the Venetian and Palazzo Resort, a hotel and casino resort located on the Las Vegas Strip.

To learn more about the A4M World Congress, visit the event website. For more information about Global Stem Cells Group, visit the GSCG website, email info@stemcellsgroup.com, or call +1305 560 5337.

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and healthcare professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

###

A4M 25th Annual World Congress

Stem Cell training Lima Peru

The International Association for Stem Cell Application (ISSCA) has announced plans to host three regenerative medicine symposiums in Istanbul, Turkey, Buenos Aires, Argentina, and Seoul, Korea in 2018. The Seoul symposium will be part of, the 6th Annual International Conference of ISSCA, “Progress and Perspectives,” which will be held in Seoul in November 2018.

 

regenerative-medicine-symposiums-2018 ISSCA

MIAMI, Nov. 9, 2017—The International Association for Stem Cell Application (ISSCA) has announced plans to host three regenerative medicine symposiums in the upcoming year:

  • Istanbul, Turkey, April 2018
  • Buenos Aires, Argentina, August 2018
  • Seoul, Korea, November 2018

The symposium series will culminate in the 6th Annual International Conference of ISSCA, Progress and Perspectives, in Seoul, Korea in November 2018.

The three international symposiums are part of ISSCA’s mission to support a paradigm shift in healthcare from traditional to regenerative medicine in the 21st Century and provide cutting-edge information on developments in all areas of stem cell research. Each event will host a group of renowned international speakers in the field of stem cell and regenerative medicine, who will offer a day of rigorous scientific discourse aimed at physicians.

Each ISSCA symposium will incorporate the biology, medicine, applications, regulations, product development, and commercialization of stem cells. Business opportunities, challenges, and potential strategies for overcoming these challenges will also be addressed.

The central theme of each international symposium is as follows:

•  Istanbul: Advances in Cell Therapies
•  Buenos Aires:  Next Generation Medicine: Adult Stem Cells
•  Seoul: This seminar will be part of the 6th Annual International Conference of ISSCA, “Progress and Perspectives”

Symposium dates and details will be available shortly. To learn more about the ISSCA symposiums and 6th Annual International Conference of ISSCA, visit the stemcellconference.org website, email info@stemcellsgroup.com, or call +1305 560 5337.

About ISSCA:

The International Society for Stem Cell Application (ISSCA) is a multidisciplinary community of scientists and physicians, all of whom aspire to treat diseases and lessen human suffering through advances in science, technology and the practice of regenerative medicine. ISSCA serves its members through advancements made to the specialty of regenerative medicine.

The ISSCA’s vision is to take a leadership position in promoting excellence and setting standards in the regenerative medicine fields of publication, research, education, training and certification.

As a medical specialty, regenerative medicine standards and certifications are essential, which is why ISSCA offers certification training in cities all over the world. The goal is to encourage more physicians to practice regenerative medicine and make it available to benefit patients both nationally and globally.  Incorporated under the Republic of Korea as a non-profit entity, the ISSCA is focused on promoting excellence and standards in the field of regenerative medicine.

.###

Regenerative medicine symposiums 2018 ISSCA

Cell Processing urn-key solution

Cell processing turn-key solution

Global Stem Cells Group and its affiliate AdiMarket announce the new Turn-Key Solution, a one-stop solution that provides high-quality stem cell processing equipment and kits and the expert help needed to set up a stem cell lab in-clinic or in-hospital.


MIAMI, Nov. 9, 2017—Global Stem Cells Group (GSCG) and its affiliate AdiMarket now offer a new, turn-key solution for stem cell processing. The AdiMarket Turn-Key Solution is a one-stop solution that provides high-quality equipment and kits required for stem cell processing and the expert help needed to set up a stem cell processing lab in-clinic or in-hospital. It can also be designed for complex protocols such as cryopreservation, culturing, and expansion of adult stem cells derived from adipose tissue and bone marrow.

Cell processing turn-key solution

GSCG and AdiMarket provide everything needed to bring this ready-to-go cell processing expansion lab to scientists andinstitutions worldwide. Physician training courses in the field of regenerative medicine are also available to qualified physicians. These expert training courses provide hands-on, practical instruction under the guidance of trained medical experts in a highly visual, interactive, and clinical learning environment.

The AdiMarket Turn-Key Solution is a complete solution for installing highly customized, in-clinic or in-hospital turn-key laboratories to meet each facility’s individual needs.

“A well-planned, organized, and properly equipped laboratory supports critical research and favorable procedure outcomes by increasing efficiency and reducing lost time and wasted resources,” says Benito Novas, Global Stem Cells Group founder and CEO.  This is vital to continuing to the discovery and implementation of new methods for treating patients.”

Admarket is GSCG’s online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals, offering all the tools and products practitioners need to facilitate in-office, in-clinic, or in-hospital stem cell procedures. From planning to building the lab, to training and consultation, Turn-Key Solution users are equipped in every way possible to walk in and begin using their fully-outfitted biotechnology lab.

To learn more about Global Stem Cells Group and the AdiMarket Turn-Key Solution, visit the GSCG website,  email info@stemcellsgroup.com, or call +1305 560 533

About Global Stem Cells Group:

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

Global stem cell’s aim is to be the largest recognized stem cell and regenerative medicine network in the world.

About Adimarket:

Adimarket, Inc., a division of the Global Stem Cells Group, is a one-stop, cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and healthcare professionals.

Adimarket was founded to provide practitioners the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting-edge treatments.

###

Cell Processing urn-key solution

 

 

 

Click on photo (at left) to enlarge
Photo: iPS cells feature – reprogrammed stem cells: Credit: Moscow Institute of Physics and Technology

Russian researchers have concluded that reprogramming does not create differences between reprogrammed and embryonic stem cells.

Stem cells are specialized, undifferentiated cells that can divide and have the remarkable potential to develop into many different cell types in the body during early life and growth. They serve as a sort of internal repair system in many tissues, dividing essentially without limit to replenish other cells. When a stem cell divides, each new cell has the potential either to remain a stem cell or become another more specialized cell type, such as a muscle cell, a red blood cell, or a brain cell. Scientists

distinguish several types of stem cells—pluripotent stem cells can potentially produce any cell in the body. No pluripotent stem cells exist in an adult body, rather they are found naturally in
early embryos.

There are two ways to harvest pluripotent stem cells. The first is to extract them from the excess embryos produced during invitro fertilization procedures, although this practice is still ethically and technically controversial because it does destroy an embryo that could have been implanted. For this reason, researchers came up with the second way to get pluripotent stem cells— reprogramming adult cells.

Reprogramming, the process of “turning on” genes that are active in a stem cell and “turning off” genes that are responsible for cell specialization was pioneered by Shinya Yamanaka, who showed that the introduction of four specific proteins essential during early embryonic development could be used to convert adult cells into pluripotent cells. Yamanaka was awarded the 2012 Nobel Prize along with Sir John Gurdon for the discovery that mature stem cells can be reprogrammed to become pluripotent.

reprogram3use

Production of iPS cells:
• Isolate cells from patient; grow in a dish •
Treat cells with “reprogramming”
• Wait a few weeks
• Pluripotent stem cells
• Change culture conditions to stimulate cells to differentiate into a variety of cell types
• blood cells  |   gut cells   |  cardio muscle cells
Credit: Moscow Institute of Physics and Technology

Thanks to their unique regenerative abilities, stem cells offer potential for treating any disease. For example, there have been cases of transplanting retinal pigment epithelium and spine cells from stem cells. Another experiment showed that stem cells were able to regenerate teeth in mice. Reprogramming holds great potential for new medical applications,  since reprogrammed pluripotent stem cells (or induced pluripotent stem cells) can be made from a patient’s own cells instead of using pluripotent cells from embryos.

However, the extent of the similarity between induced pluripotent stem cells and human embryonic stem cells remains unclear. Recent studies highlighted significant differences between these two types of stem cells, although only a limited number of cell lines of different origins were analyzed.

Researchers compared induced pluripotent stem cell (iPSC) lines reprogrammed from adult cell types that were previously differentiated from embryonic stem cells. All these cells were isogenic, meaning they all had the same gene set.

Scientists analyzed the transcriptome – the set of all products encoded, synthesized and used in a cell. Moreover, they elicited methylated DNA areas, because methylation plays a critical role in cell specialization. Comprehensive studies of changes in the gene activity regulation mechanism showed similarities between reprogrammed and embryonic stem cells. In addition, researchers produced a list of the activity of 275 key genes that can present reprogramming results.

Researchers studied three types of adult cells – fibroblasts, retinal pigment epithelium and neural cells, all of which consist of the same gene set; but a chemical modification (e.g. methylation) combined with other changes determines which part of DNA will be used for product synthesis.

Scientists concluded that the type of adult cells that were reprogrammed and the process of reprogramming did not leave any marks. Differences between cells that did occur were thought to be the result of random factors.

“We defined the best induced pluripotent stem cells line concept,” says Dmitry Ischenko, MIPT Ph.D. and Institute of Physical Chemical Medicine researcher.

The minimum number of iPSC clones that would be enough for at least one to be similar to embryonic pluripotent cells with 95 percent confidence is five.”

programmed stem cellsClearly, no one is going to convert embryonic stem cells into neurons and reprogram them into induced stem cells. Such a process would be too time-consuming and expensive. This experiment simulated the reprogramming of a patient’s adult cells into induced pluripotent stem cells for further medical use, and even though the reprogramming paper, published in the journal Cell Cycle, does not currently propose a method of organ growth in vitro, it is an important step in the right direction. Both induced pluripotent cells and embryonic stem cells can help researchers understand how specialized cells develop from pluripotent cells. In the future, they may also provide an unlimited supply of replacement cells and tissues that can benefit many patients with diseases that are currently untreatable.

The study, titled, “An integrative analysis of reprogramming in human isogenic system identified a clone selection criterion,” concluded that reprogramming does not create differences between reprogrammed and embryonic stem cells, involved researchers from the Vavilov Institute of General Genetics, Research Institute of Physical Chemical Medicine, and the Moscow Institute of Physics and Technology (MIPT).

###

human stem cells

Scientists from the U.K. and Sweden have discovered a new method of creating human stem cells that could solve the problem of meeting large-scale production needs, allowing researchers to fully realize the potential of stem cells for understanding and treating disease.

Human pluripotent stem cells are undifferentiated cells that have the unique potential to develop into all the different types of
cells in the body. With applications in disease modeling, drug screening, regenerative medicine and tissue engineering, there is already an enormous demand for these cells, and that demand will continue grow as their use in clinical settings and the pharmaceutical industry increases.

Human embryonic stem cell line HUES1 grown in the new conditions E8+Inter-alpha-inhibitor and imaged for stem cell marker Oct4 (green) and cell-cell attachment molecule E-cadherin (red) with nuclear counter-staining (blue). Credit: Dr. Sara Pijuan-Galito and Dr. Cathy Merry, Wolfson Centre for Stem Cells, Tissue Engineering & Modelling and Centre for Biomolecular Sciences, The University of Nottingham Read more at: http://phys.org/news/2016-07-breakthrough-scaling-life-changing-stem-cell_line

Human embryonic stem cell line HUES1 grown in the new conditions E8+Inter-alpha-inhibitor and imaged for stem cell marker Oct4 (green) and cell-cell attachment molecule E-cadherin (red) with nuclear counter-staining (blue).
Credit: Dr. Sara Pijuan-Galito and Dr. Cathy Merry, Wolfson Centre for Stem Cells, Tissue Engineering & Modelling and Centre for Biomolecular Sciences, The University of Nottingham.

However, production of stem cells at the scale required for optimal application in modern research and healthcare has not beenfeasible because available culture methods are either too expensive, or reliant on substances that would not be safe for clinical use in humans.

The research results, published in Nature Communications in July, describe how the scientific team from The University of Nottingham’s Wolfson Centre for Stem Cells, Tissue Engineering and Modelling at Uppsala University in Sweden and GE Healthcare also in Sweden have identified and improved human stem cell culture methods that could lead to quicker and cheaper large scale industrial production of human pluripotent stem cells.

By using a protein derived from human blood called Inter-alpha inhibitor, the team has grown human pluripotent stem cells in a minimal medium without the need for costly and time-consuming biological substrates. Inter-alpha inhibitor is found in human blood at high concentrations, and is currently a by-product of standard drug purification schemes.

The human serum-derived protein can make stem cells attach to unmodified tissue culture plastic, eliminating the need for coating in defined human pluripotent stem cell culture, and improving survival capabilities of the stem cells in harsh conditions.

It is the first stem cell culture method that does not require a pre-treated biological substrate for attachment, and therefore, is more cost and time efficient, paving the way for easier and cheaper large-scale production.

Existing methods are time consuming and make developing human stem cell cultures prohibitively costly. This new method has the potential to save time and money in large-scale and high-throughput cultures, and be highly valuable for both basic research and commercial applications.

The work began at Uppsala University, and the study’s first author, Sara Pijuan-Galitó PhD., is continuing her work as a Swedish Research Council Research Fellow at Nottingham.

Researchers now intend to combine Inter-alpha inhibitor protein with an innovative hydrogel technology to improve on current methods for controlling cell differentiation, and also apply it to disease modelling. The discovery, according to the findings, will help facilitate research into many diseases although their focus is currently on understanding rare conditions like Multiple Osteochondroma) at the cellular level. The aim is to replicate the 3 dimensional environment that cells experience within the body so that lab-bench biology is more accurate in modelling diseases.

Pijuan-Galitó has been awarded the Sir Henry Wellcome Postdoctoral Fellowship at Nottingham University for her work on the research, which will enable her to combine Inter-alpha inhibitor with improved synthetic polymers in collaboration with fellow regenerative medicine pioneers Professor Morgan Alexander and Professor Chris Denning. The team plans to further improve on current human stem cell culture by designing an economical and safe method that can be easily translated to large-scale production and can deliver billions of stem cells necessary move cellular therapeutics forward in patient settings.

The study, titled “Human serum-derived protein removes the need for coating in defined human pluripotent stem cell culture,” was published in Nature Communications in July, 2016.

###